Intuitive Surgical Fell 40% — The Real Question Is Whether the Slowdown Is Temporary

Intuitive Surgical did the hard thing in its June quarter: it beat. Revenue rose 19% to $2.89 billion, and adjusted earnings came in at $2.80 a share. And the stock still fell almost 11% after the close, one more step in a selloff that has left shares down roughly 40% from their 2025 peak. When a quality compounder drops on an earnings beat, the question is not whether the quarter was good. It is whether the market is pricing a broken story or a temporary slowdown.

So far, the evidence points to a slowdown — a real one, but a deceleration rather than a collapse.

The market repriced growth that had already cooled

The number investors were watching was procedures, the operations done on Intuitive's $2-million robots and Ion lung probe. In the second quarter, worldwide procedures grew about 16% from a year earlier — da Vinci procedures up 15%, Ion up a faster 36%. That is the deceleration: procedure growth has cooled into the mid-teens as the year rolled on, and management now guides full-year 2026 da Vinci procedure growth to 13.5% to 15.5%, expecting to land near the middle.

Why the cool-down? Intuitive's own commentary points to slower U.S. growth from hospital funding uncertainty and pressure on weight-loss surgery demand from the rise of anti-obesity drugs — procedures being delayed, not lost — alongside tariff drag, plus competition from domestic rivals in China. None of that is pleasant, but the slowdown is precisely what the market has spent 2026 repricing.

The business underneath never broke

Set the tape aside and look at the cash-flow path, which is where the operating story actually lives. Over the last twelve months Intuitive generated about $3.2 billion of free cash flow, up more than 60% year over year, on revenue growing close to 21%. It holds net cash — $2.76 billion of cash against $2.58 billion of debt — and returns on invested capital near 15.5%. The installed base that drives the recurring revenue is still expanding: more than 11,700 da Vinci systems, with the newest da Vinci 5 "still early in its rollout."

That is the gap the moment hinges on. The stock is lower, but the numbers that promise future cash are not. Executives on the call described an actual 2027 product path: beginning in the first half of 2027, they plan to introduce an updated subset of EndoWrist instruments for the fourth- and fifth-generation systems — the instruments that generate the recurring revenue — plus the still-ramping da Vinci 5 installed base. A beaten-down name with an intact engine and a dated product cycle ahead is closer to the pattern worth studying than a broken one.

Now the uncomfortable part: it is not cheap

Here is where a beaten-down stock can fool you. Even after a 40% drawdown, Intuitive still trades near 46 times forward earnings and roughly 39 times trailing free cash flow. Those are not bargain multiples; that is an expensive compounder that has simply come down from an even more expensive level.

So the honest framing is not "buy the dip." The market has reset its expectations — the bar for surprise is lower than it was a year ago — but an entry today means paying roughly 39 times this year's cash flow for the bet that the slowdown is temporary and the 2027 instrument cycle re-accelerates the recurring-revenue machine. The proof path is concrete: do procedure growth numbers hold near the guided 13.5% to 15.5%, and does free cash flow keep compounding while the da Vinci 5 base expands?

What would break the case

The strongest bear argument is simple: at these multiples, the stock only works if growth restores. The specific condition that trips the rerating story is procedure growth slipping through the low end of that guided range, or U.S. funding headwinds crystallizing into cancelled rather than delayed procedures, combined with fresh tariff or China competition pressure. In that world, the multiple does not re-rate — it compresses further.

I can be wrong again; the whole thesis relies on the slowdown being temporary. But the setup is cleaner than the tape suggests. Intuitive Surgical is not the obvious scratch-and-dent bargain the 40% drop implies — it still costs almost 39 times free cash flow. It is, instead, a quality compounder whose market bar has been lowered while the operating engine kept compounding. That is a name to understand and watch, with the procedure-growth guide as the tripwire, not one to chase on the headline.